Tilray Brands, Inc. reported a Q3 net loss of $25.2 million, an improvement from last year's massive loss, while revenue rose 11% to $206.7 million, driven by strong cannabis sales and international growth. The company is transforming its business model, acquiring BrewDog's assets and entering a licensing partnership with Carlsberg to diversify offerings. As regulatory shifts raise hopes for increased capital flow in the cannabis sector, Tilray faces investor skepticism due to ongoing profitability challenges and share dilution concerns.
“Medicare lawsuit changes the game. Watch demand and $MSOS $TLRY setups.”
“$TLRY NEEDS $7.08 BREAK https://t.co/q4bzx1WiNU”
“$TLRY | Tilray Brands reports Q3 loss of $25.2M, or 24 cents a share, significantly narrowing from a loss of $793.5M last year.”
“The company also announced a deal to acquire BrewDog's global brand and U.S. assets.”
“Revenue rose 11% to $206.7M, driven by a 19% increase in cannabis sales and a 16% rise in wellness segment revenue.”
“$MSOS moving, $TLRY setup for upside. Watch banking risk, size your bets.”
“Policy split in cannabis - LA medical wins, MO hemp-THC bans. Eyes on $TLRY $MSOS setups.”
“Policy tailwind: federal + state moves flip the script. Eyes on $MSOS $TLRY - hemp in Medicare Advantage opens capital flows. Watch.”
“Legal storms crush cannabis runs. Eyes on $TLRY $MSOS — regulation risk pins pot plays, setups failing.”
“Eyes on rescheduling & FDA CBD memo. States moving — watch $TLRY $MSOS setups into legalization.”
“One of its signature stocks, Tilray Brands(NASDAQ: TLRY), is a case in point; the company is chronically unprofitable and, year to date, its shares are down by more than 12%.”
“That's a lot more than we can say for most pure-play marijuana companies, Tilray included.”